Possible effects of neonatal vitamin B12 status on TSH-screening program: a cross-sectional study from Turkey

Author(s):  
Zerrin Onal ◽  
Seda Balkaya ◽  
Atilla Ersen ◽  
Neval Mutlu ◽  
Hasan Onal ◽  
...  

AbstractBackground:In this study we evaluated whether vitamin B12 deficiency affects neonatal screening (NS) for congenital hypothyroidism (CH).Methods:A cross-sectional study conducted from 2010 to 2011. A total of 10,740 infants were born in our hospital in this period. Thyroid-stimulating hormone (TSH) was tested for NS and neonates with abnormal screening results (TSH>20 mIU/L) were re-examined. Two hundred and twenty-nine re-called subjects (re-call rate 2.3%) were compared to 77 randomly selected newborns with normal TSH screening among these term newborns in terms of serum TSH, free T4, vitamin B12 and homocysteine status.Results:Of the 229 re-called subjects, 11 infants with CH and 21 infants with transient TSH elevation were detected. In the normal TSH screening group, only two infants were diagnosed with transient TSH elevation. Mean serum B12 levels were 126.4±48.7 pg/mL and 211.9±127.9 pg/mL in the positive TSH-screening group and the control group, respectively. There was a significant difference between positive and normal TSH-screening groups in regard to serum TSH, free T4, serum B12 and homocysteine levels.Conclusions:We found a significant vitamin B12 deficiency in positive TSH-screening infants. Beside the crucial role of vitamin B12 in newborns, deficiency seems to increase the recall rates of infants in an NS program for CH.

Medicina ◽  
2020 ◽  
Vol 56 (3) ◽  
pp. 142
Author(s):  
Osama Y. Al-Dirbashi ◽  
Charu Sharma ◽  
Nahid Al Dahouri ◽  
Anas Al Aidaros ◽  
Shamma Al-Muhairi ◽  
...  

Background and objectives: Although laparoscopic sleeve gastrectomy (LSG) is effective for obesity management, postoperative vitamin B12 (B12) deficiency is of major concern. In this cross-sectional study, we assessed the levels of B12 and its related functional biomarkers, namely, total homocysteine (tHcy), methylmalonic acid (MMA), folate, methylcitric acid (MCA), and hemoglobin (Hb), in one-year postoperative LSG patients and matched controls. Materials and Methods: Plasma B12, tHcy, MMA, folate, and MCA were measured in matched controls (n = 66) and patients (n = 71) using validated liquid chromatography-tandem mass spectrometry techniques and protocols in the United Arab Emirates (UAE). Results: The median B12 concentration in patients (177 pmol/L) was significantly lower (p < 0.001) than in the controls (334.7 pmol/L). The tHcy and MMA levels were significantly increased (p < 0.001 and p = 0.011, respectively) and folate levels were significantly decreased (p = 0.001) in the LSG patients compared to the controls. Interestingly, no significant difference in MCA levels were observed between the two groups. The levels of tHcy and MMA were concomitantly increased with the decreased folate levels in postoperative LSG patients when compared with the controls. The Hb levels were significantly lower in males and females in the patient group compared with those in the control group, respectively (p = 0.005 and p = 0.043). Conclusions: This is the first report of serum levels of B12 and its functional biomarkers in postoperative LSG patients among a local population from the UAE. Our findings revealed significant alterations of the B12 biomarkers, total B12, MMA, and tHcy in one-year postoperative LSG patients.


2016 ◽  
Vol 134 (6) ◽  
pp. 473-479 ◽  
Author(s):  
Charbel Pereira Damião ◽  
Amannda Oliveira Rodrigues ◽  
Maria Fernanda Miguens Castellar Pinheiro ◽  
Rubens Antunes da Cruz Filho ◽  
Gilberto Peres Cardoso ◽  
...  

ABSTRACT: CONTEXT AND OBJECTIVE: The prevalence of vitamin B12 deficiency varies from 5.8% to 30% among patients undergoing long-term treatment with metformin. Because of the paucity of data on Brazilian patients, this study aimed to determine the frequency of B12 deficiency and related factors among Brazilian patients with type 2 diabetes mellitus (T2DM) using metformin. DESIGN AND SETTING: Cross-sectional study at a public university hospital. METHODS: Patients with T2DM and a control group of non-diabetics were included. Serum B12 levels were measured and biochemical B12 deficiency was defined as serum levels < 180 pg/ml. Associations between B12 deficiency and age, duration of T2DM, duration of use and dosage of metformin, and use of proton pump inhibitors (PPIs) or histamine H2 antagonists were determined. RESULTS: 231 T2DM patients using metformin (T2DM-met) and 231 controls were included. No difference in the frequency of PPI or H2-antagonist use was seen between the groups. B12 deficiency was more frequent in the T2DM-met group (22.5% versus 7.4%) and this difference persisted after excluding PPI/H2-antagonist users (17.9% versus 5.6%). The factors that interfered with serum B12 levels were PPI/H2-antagonist use and duration of metformin use ≥ 10 years. Use of PPI/H2-antagonists was associated with B12 deficiency, with an odds ratio of 2.60 (95% confidence interval, 1.34-5.04). CONCLUSIONS: Among T2DM patients, treatment with metformin and concomitant use of PPI/H2-antagonists are associated with a higher chance of developing B12 deficiency than among non-diabetics.


2020 ◽  
Vol 20 (1) ◽  
pp. 90
Author(s):  
Ahmed Al-Hamdi ◽  
Mohammed Al-Gahhafi ◽  
Shihab Al-Roshdi ◽  
Sanjay Jaju ◽  
Ali Al-Mamari ◽  
...  

Objectives: This study aimed to determine the prevalence of vitamin B12 deficiency amongst diabetic patients on metformin therapy. Methods: This cross-sectional study was conducted at general clinics at the University Health Center and diabetes outpatient clinics at Sultan Qaboos University Hospital, Muscat, Oman, between January and December 2017. All Omani adults who were diagnosed with type 2 diabetes mellitus and took metformin were invited to participate in the study. The variables included in this study were age, gender, duration of diabetes, dose and duration of metformin therapy, haemoglobin and glycosylated haemoglobin level. Results: A total of 248 subjects were included (response rate = 95.4%) of which 26 (10.5%) were vitamin B12 deficient and 53 (21.4%) were borderline deficient. The mean daily dose of metformin was highest among vitamin B12 deficient group (1,981 ± 222 mg; P = 0.004). Conclusion: The prevalence of vitamin B12 deficiency is considerable among diabetic patients on metformin therapy. Further research is needed to confirm the need for routine screening and monitoring.Keywords: Type 2 Diabetes Mellitus; Prevalence; Metformin; Vitamin B12 Deficiency; Oman.


2018 ◽  
Vol 72 (4) ◽  
pp. 265-271 ◽  
Author(s):  
Ili Margalit ◽  
Eytan Cohen ◽  
Elad Goldberg ◽  
Ilan Krause

Background: Vitamin B12 deficiency is associated with hematological, neurological, and cardiovascular consequences. Epidemiologic data on these related illnesses indicate gender differences. Methods: A cross-sectional study was designed to examine gender differences in vitamin B12 deficiency among a healthy population. Data from healthy individuals aged 18–65, who were provided with a routine medical evaluation during 2000–2014, were retrieved from the medical charts. Individuals with background illnesses and those who had used medications or nutritional supplements were excluded. Vitamin B12 deficiency was defined by 2 cutoff values (206 and 140 pmol/L). The multivariate analysis was adjusted for age, body mass index, estimated glomerular filtration rate, hyperhomocysteinemia, folate deficiency, albumin, and transferrin saturation. Sensitivity analyses were implemented by excluding individuals with anemia, hyperhomocysteinemia, or folate deficiency and by age stratification. Results: In all, 7,963 individuals met the inclusion criteria. Serum vitamin B12 mean levels were 312.36 and 284.31 pmol/L for women and men respectively (p < 0.001). Deficiency prevalence was greater for men (25.5%) in comparison with women (18.9%; p < 0.001). Men were strongly associated with severe deficiency (adjusted OR 2.26; 95% CI 1.43–3.56). Conclusions: Among the healthy population, men are susceptible to vitamin B12 deficiency. This can be explained by neither diet habits nor estrogen effects. Genetic variations are therefore hypothesized to play a role.


2009 ◽  
Vol 22 (5) ◽  
pp. 528-534 ◽  
Author(s):  
M. C. Pflipsen ◽  
R. C. Oh ◽  
A. Saguil ◽  
D. A. Seehusen ◽  
D. Seaquist ◽  
...  

2021 ◽  
Vol 8 (32) ◽  
pp. 3012-3017
Author(s):  
Kunal Lala ◽  
Divya Lala ◽  
Saurabh Duggad

BACKGROUND Metformin is reported to induce vitamin B12 deficiency and distinguishing peripheral neuropathy due to vitamin B12 deficiency from diabetic peripheral neuropathy can be challenging. The present study was conducted to assess and compare the clinical presentation of diabetic patients taking metformin with those not taking metformin using Toronto clinical scoring system (TCSS). METHODS This cross-sectional study included 60 patients with diabetes mellitus, 30 patients on metformin therapy (at least 6 months) and 30 patients not on metformin use. Clinical presentation of the patients was assessed using the TCSS. Patients were diagnosed according to the American diabetic association criteria. RESULTS The mean age of the patients in metformin and non-metformin group was 57.27 ± 9.38 and 58.63 ± 10.27 years respectively. Gender distribution was observed to be similar in both the study groups. Mean duration of diabetes mellitus was found to be similar in both the study groups (5.4 ± 1.01 vs 5.2 ± 1.27 years) and duration of peripheral neuropathy was also found to be similar in the two study groups (3.2 ± 1.6 vs 3.3 ± 1.5 years). Numbness was observed in maximum number of cases in both study groups. It was seen in 100 % (n = 30) patients on metformin drug while in 90 % (n = 27) patients without metformin. Pain accounts to be approximately 77 % (n = 23) and 24 % (n = 7) in patients on metformin and without metformin. Neuropathic symptoms and neuropathic reflex scoring appear to be higher common in patients on metformin as compared to those without metformin. Mean pain score was found to be significantly higher among patients on metformin as compared to those not on metformin (8.43 ± 2.13 vs 4.03 ± 3.13; P value < 0.001). CONCLUSIONS Our results show that patients on metformin for diabetes mellitus experience higher neuropathic symptoms as compared to those not taking metformin. KEYWORDS Diabetes Mellitus, Metformin, Peripheral Neuropathy, Vitamin B12


Sign in / Sign up

Export Citation Format

Share Document